NCT05783622 - Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2027

Conditions

Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckColorectal CarcinomaSmall Cell Lung CancerPancreatic Ductal AdenocarcinomaTriple-negative Breast Cancer

Interventions

DRUG

JANX008

JANX008 is dosed via IV weekly in a 21-day cycle

Trial Locations (18)

10016

RECRUITING

Laura and Isaac Perlmutter Cancer Center NYU Langone Health, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

19104

RECRUITING

University of Pennsylvania, Abramson Cancer Center, Philadelphia

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

30308

RECRUITING

Winship Cancer Institute, Emory University, Atlanta

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

43210

RECRUITING

Ohio State University Hospital, Columbus

45219

RECRUITING

The Christ Hospital Cancer Center, Cincinnati

48109

RECRUITING

University of Michigan, Ann Arbor

48202

RECRUITING

Henry Ford Health System, Detroit

60637

RECRUITING

University of Chicago Medical Center, Chicago

63110

RECRUITING

Washington University, St Louis

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

77030

RECRUITING

The University of Texas, MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope Medical Center, Duarte

92093

RECRUITING

University of California San Diego Moores Cancer Center, San Diego

95817

RECRUITING

University of California, Davis Comprehensive Cancer Center, Sacramento

02903

RECRUITING

Rhode Island Hospital, Providence